AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-09-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-1179PMID 27663586PMCID PMC5354947
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

  2016cited by this paper
• Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

  2015cited by this paper
• Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins.

  2015cited by this paper
• Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.

  2015cited by this paper
• XAV939-Mediated ARTD Activity Inhibition in Human MB Cell Lines

  2015cited by this paper
• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

  2015cited by this paper
• Less Toxic Chemotherapy Improves Uptake of All Lines of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A 10-Year Retrospective Population-Based Review

  2014cited by this paper
• Flavonoids and Wnt/β-Catenin Signaling: Potential Role in Colorectal Cancer Therapies

  2014cited by this paper
• Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.

  2014cited by this paper
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

  2014cited by this paper
• β-catenin contributes to lung tumor development induced by EGFR mutations.

  2014cited by this paper
• Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome

  2013cited by this paper
• A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.

  2013influential reference
• Fermat , Schubert , Einstein , and Behrens-Fisher : The Probable Difference Between Two Means When F 12 ... F 22

  2013cited by this paper
• Evidence for tankyrases as antineoplastic targets in lung cancer

  2013cited by this paper
• Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.

  2013cited by this paper
• Inhibition of Tankyrases Induces Axin Stabilization and Blocks Wnt Signalling in Breast Cancer Cells

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• Tankyrase-targeted therapeutics: expanding opportunities in the PARP family

  2012cited by this paper
• A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.

  2012cited by this paper
• β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer

  2012cited by this paper
• Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

  2012influential reference
• Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

  2012cited by this paper
• Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex.

  2012cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Lentiviral Vectors to Probe and Manipulate the Wnt Signaling Pathway

  2010cited by this paper
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

  2010cited by this paper
• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

  2009cited by this paper
• Wnt/beta-catenin signaling: components, mechanisms, and diseases.

  2009cited by this paper
• Drugging the Wnt pathway: problems and progress.

  2009cited by this paper
• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  2008cited by this paper
• Wnt1 overexpression associated with tumor proliferation and a poor prognosis in non-small cell lung cancer patients.

  2008cited by this paper
• Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer

  2008cited by this paper
• The Role of the Poly(ADP-ribose) Polymerase Tankyrase1 in Telomere Length Control by the TRF1 Component of the Shelterin Complex*

  2007cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?

  2007cited by this paper
• New molecularly targeted therapies for lung cancer.

  2007cited by this paper
• Mining the Wnt pathway for cancer therapeutics

  2007cited by this paper
• Dysregulation of growth factor signaling in human hepatocellular carcinoma

  2006cited by this paper
• Abnormal beta-catenin and reduced axin expression are associated with poor differentiation and progression in non-small cell lung cancer.

  2006cited by this paper
• Abnormal β-Catenin and Reduced Axin Expression Are Associated With Poor Differentiation and Progression in Non–Small Cell Lung Cancer

  2006cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• Resolution of Sister Telomere Association Is Required for Progression Through Mitosis

  2004cited by this paper
• Mutations of the β- and γ-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas

  2001cited by this paper
• Constitutive activation of the Wnt signaling pathway by CTNNB1 (β‐catenin) mutations in a subset of human lung adenocarcinoma

  2001cited by this paper
• β-Catenin Dysregulation in Thyroid Neoplasms : Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis

  2001cited by this paper
• b -Catenin Dysregulation in Thyroid Neoplasms Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis

  2001cited by this paper
• Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis.

  2001cited by this paper
• AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1

  2000cited by this paper
• Sporadic medulloblastomas contain oncogenic beta-catenin mutations.

  1998cited by this paper
• Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas.

  1998cited by this paper
• Sporadic Medulloblastomas Contain Oncogenic β-Catenin Mutations

  1998cited by this paper
• Mutations in the β-Catenin Gene (CTNNB1) in Endometrioid Ovarian Carcinomas

  1998cited by this paper
• Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC

  1997cited by this paper
• Cancer statistics

  1989cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• The role of microRNAs in modulating Wnt signaling pathway dynamics and their therapeutic implications in non-small cell lung cancer.

  2026cites this paper
• Understanding Tankyrase Inhibitors and Their Role in the Management of Different Cancer.

  2025cites this paper
• Evolutionary conservation and cancer implications of the WNT signaling pathway

  2025cites this paper
• CREB Regulates Cisplatin Resistance by Targeting TNKS and KDM6A in NSCLC cell-Derived Tumor Spheroid

  2025cites this paper
• Anti-galectin-9 therapy synergizes with EGFR inhibition to reprogram the tumor microenvironment and overcome immune evasion

  2025cites this paper
• Targeting the Wnt/β-catenin signal pathway for the treatment of gastrointestinal cancer: Potential for advancement.

  2024cites this paper
• Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer

  2024cites this paper
• CTNNB1 exon 3 mutations in metastatic solid pseudopapillary neoplasm of the pancreas

  2024cites this paper
• PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer

  2024cites this paper
• Wnt Signaling in Brain Tumors: A Challenging Therapeutic Target

  2023cites this paper
• Natural compounds: Wnt pathway inhibitors with therapeutic potential in lung cancer

  2023cites this paper
• WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice

  2023influential citation
• A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities

  2023cites this paper
• Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer.

  2022cites this paper
• EGFR TKI resistance in lung cancer cells using RNA sequencing and analytical bioinformatics tools

  2022cites this paper
• Assessing the performance of different outcomes for tumor growth studies with animal models

  2022cites this paper
• Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract.

  2022cites this paper
• Signaling pathways and their potential therapeutic utility in esophageal squamous cell carcinoma

  2022cites this paper
• Wnt/β-catenin signaling in cancers and targeted therapies

  2021cites this paper
• Precision Oncology, Signaling and Anticancer Agents in Cancer Therapeutics.

  2021cites this paper
• Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer.

  2021cites this paper
• The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies

  2021cites this paper
• Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities

  2021cites this paper
• C644‐0303, a small‐molecule inhibitor of the Wnt/β‐catenin pathway, suppresses colorectal cancer growth

  2021cites this paper
• The multidimensional role of the Wnt/β‐catenin signaling pathway in human malignancies

  2021cites this paper
• Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials

  2021cites this paper
• Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views

  2020cites this paper
• CMAR_A_258645 6987..6998

  2020cites this paper
• Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex

  2020cites this paper
• Sjögren syndrome/scleroderma autoantigen 1 is a direct Tankyrase binding partner in cancer cells

  2020cites this paper
• Design and Discovery of an Orally Efficacious Spiroindolinone-based Tankyrase Inhibitor for the Treatment of Colon Cancer.

  2020cites this paper
• New molecular insights into dual inhibitors of tankyrase as Wnt signaling antagonists: 3D-QSAR studies on 4H-1,2,4-triazole derivatives for the design of novel anticancer agents

  2020cites this paper
• New Advances in Canonical Wnt/β-Catenin Signaling in Cancer

  2020cites this paper
• Wnt Signaling in the Regulation of Immune Cell and Cancer Therapeutics

  2019influential citation
• Exploring the molecular mechanisms of Traditional Chinese Medicine components using gene expression signatures and connectivity map

  2019cites this paper
• Negative regulators of Wnt signaling in non-small cell lung cancer: Theoretical basis and therapeutic potency.

  2019cites this paper
• Poly(ADP-ribose) polymerase enzymes and the maintenance of genome integrity

  2019cites this paper
• Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.

  2019cites this paper
• Wnt Signaling and Drug Resistance in Cancer

  2019cites this paper
• Urea Cycle Sustains Cellular Energetics upon EGFR Inhibition in EGFR-Mutant NSCLC

  2019cites this paper
• Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2

  2019cites this paper
• A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer

  2019cites this paper
• Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities

  2018cites this paper
• Efflux inhibition by IWR‐1‐endo confers sensitivity to doxorubicin effects in osteosarcoma cells

  2018cites this paper
• Tankyrase: Function and Tankyrase Inhibitor in Cancer

  2018cites this paper
• WNT Signaling in Cardiac and Vascular Disease

  2018cites this paper
• Regulation of microRNAs function by circular RNAs in human cancer

  2017cites this paper
• Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.

  2017cites this paper
• Wnt signaling in the vessel wall

  2017cites this paper
• Primary Double‐Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench

  2017cites this paper
• Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer

  2017influential citation
• Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)

  2017cites this paper
• Molecular genetics and targeted therapy of WNT-related human diseases (Review)

  2017influential citation
• Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.

  2017cites this paper